Delivering Value To Those We Serve

Overview

Recent News

Date Title and Summary
Toggle Summary Assertio Reports Second Quarter 2020 Financial Results
--Completed all merger and integration activities in Q2-- --Repaid $10 million of Senior Secured Notes ahead of schedule-- --Zyla products partially contributed to Q2 net product sales of $20.2 million -- --Combined second quarter 2020 net product sales of $27.7 million , on a pro forma basis,
Toggle Summary Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020
LAKE FOREST, Ill. , July 20, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2020 financial results will be released on Friday, August 7, 2020 .
Toggle Summary Assertio Completed Merger with Zyla Life Sciences
Trading under ASRT on Nasdaq Global Select Market Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million¹ Upwards of $40 million in Expected Cost Synergies LAKE FOREST, Ill. , May 20, 2020 /PRNewswire/ -- Assertio Holdings, Inc., the successor issuer to Assertio

Upcoming Events

There are currently no events to display.
Presentations

IR Contact

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
Phone: 800.509.5586
http://www.continentalstock.com
 

Independent Registered Public Accounting Firm

Ernst & Young LLP
Palo Alto, CA
 

Investor Relations Contact

investor@assertiotx.com